HIV阳性与阴性男性接种四价HPV疫苗后口腔及全身抗体动力学研究
本研究评估了147名HIV阴性男性和75名HIV阳性男性接种三剂四价HPV疫苗后18个月内口腔和全身HPV-16/18抗体水平。所有接种者均发生血清转换,但HIV阳性男性在接种后7个月时血清抗体几何平均水平和抗体亲和力较低,而18个月时两组抗体水平无显著差异。
要点
- 三剂四价HPV疫苗后所有男性均血清转换,HIV状态不影响血清转换。
- HIV阳性男性接种后7个月血清HPV-16/18抗体水平显著低于HIV阴性男性。
- 18个月时两组抗体水平无显著差异,抗体亲和力在两组均较高。
核心结论
- HIV阳性与阴性男性接种三剂四价HPV疫苗后均产生抗体应答,尽管HIV阳性男性峰值抗体水平较低,但平台期抗体水平总体相当。
- 疫苗在两组中均诱导抗体亲和力成熟,可能产生长期保护性免疫应答。
研究设计与样本
- 研究纳入147名27-45岁HIV阴性男性和75名22-61岁HIV阳性男性,均接种三剂四价HPV疫苗。
- 在接种前、第7个月(第三剂后1个月)和第18个月(第三剂后12个月)检测血清和口腔漱液中的HPV-16/18抗体,并在接种前和第7个月检测抗体亲和力。
主要发现
- 第7个月时HIV阳性男性血清HPV-16抗体几何平均浓度为808.5 EU/mL,低于HIV阴性男性的2119.8 EU/mL(p < 0.001)。
- 第7个月时HIV阳性男性血清HPV-18抗体几何平均浓度为285.8 EU/mL,低于HIV阴性男性的611.6 EU/mL(p < 0.001)。
- 第18个月时两组血清HPV-16抗体水平分别为281.8 EU/mL和359.7 EU/mL(p = 0.145),HPV-18抗体水平分别为120.2 EU/mL和93.4 EU/mL(p = 0.372)。
- 第7个月时仅口腔HPV-16抗体水平在两组间有显著差异(HIV阳性127.7 EU/mg IgG vs HIV阴性177.1 EU/mg IgG,p = 0.008)。
- 在基线HPV血清阴性的男性中,HIV阳性男性第7和18个月时循环HPV-16/18抗体水平最多低3倍以上;而在基线血清阳性的HIV阳性男性中,接种后抗体水平不劣于HIV阴性男性。
关键数值与推荐
- 第7个月时HIV阳性男性HPV-16抗体亲和力为1.95 M,低于HIV阴性男性的2.12 M(p = 0.027)。
- 第7个月时HIV阳性男性HPV-18抗体亲和力为1.50 M,低于HIV阴性男性的1.72 M(p < 0.001)。
临床怎么用
- HIV阳性男性接种三剂四价HPV疫苗后仍可产生较高的平台期抗体水平和抗体亲和力,支持该人群接种疫苗。
- 对于基线HPV血清阴性的HIV阳性男性,接种后抗体水平较低,可能需要关注其长期保护效果。
局限性
- 研究随访时间为18个月,长期抗体持久性和保护效果需进一步研究。
- 样本量有限,且未报告临床终点(如HPV感染或病变)数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Duration and functional aspects of the oral and systemic antibody responses following HPV vaccination in HIV-negative (HIV-) and HIV-positive (HIV+) men are not well characterized. Oral and systemic HPV-16 and HPV-18-specific antibody levels were evaluated over 18-months of follow-up, in HIV+ and HIV- men. Sera and oral gargles from 147 HIV- men, ages 27-45 and 75 HIV+ men, ages 22-61, who received 3-doses of quadrivalent HPV vaccine were tested for HPV-16 and HPV-18 antibodies at Day 1, Month 7 (1 month post-dose 3), and Month 18 (12 months post-dose 3) and HPV avidity (Day 1, and Month 7) using L1-VLP ELISA. All individuals seroconverted, regardless of HIV-status, following 3-doses of vaccine for HPV-16 and HPV-18. Serum HPV-16 and HPV-18 antibody geometric mean levels were >2-fold lower in HIV+ compared to HIV- men at Month 7 (HPV-16: 808.5 versus 2119.8 EU/mL, and HPV-18: 285.8 versus 611.6 EU/mL, p < 0.001) but not significantly different at Month 18 (HPV-16: 281.8 versus 359.7 EU/mL, p = 0.145, and HPV-18: 120.2 versus 93.4 EU/mL, p = 0.372). Post-vaccination, only oral HPV-16 antibody levels at Month 7 were significantly different between HIV+ and HIV- men (127.7 versus 177.1 EU/mg of IgG, p = 0.008). Among baseline HPV-seronegative men, circulating levels of HPV-16 and HPV-18 antibodies were up to >3 fold lower in HIV+ men, at Months 7 and 18. In contrast, levels of HPV-16 and HPV-18 antibodies after vaccination were not inferior in baseline HPV-seropositive, HIV+ men. HPV-16 and HPV-18 avidity was lower among HIV+ compared to HIV- men at Month 7 (HPV-16: 1.95 M versus 2.12 M, p = 0.027; HPV-18: 1.50 M versus 1.72 M, p < 0.001). Although differences in peak antibody levels were observed between HIV+ and HIV- men following 3 doses of vaccine, plateau antibody levels were overall comparable, and avidity was relatively high for both groups. These data indicate that the vaccine induced antibody affinity maturation in both HIV+ and HIV- men and will likely result in long-term protective immune responses.
引用
- Pinto LA, Wilkin TJ, Kemp TJ, et al. Oral and systemic HPV antibody kinetics post-vaccination among HIV-positive and HIV-negative men. Vaccine. 2019. PMID: 30940485. doi:10.1016/j.vaccine.2019.03.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。